Analyzing the influence of BDNF heterozygosity on spatial memory response to 17β-estradiol

Translational Psychiatry

Volumn 5, Issue 1, 2015, Pages

  Wu, Y W C ^a   Du, X ^a   Van Den Buuse, M ^a,b   Hill, R A ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b LA TROBE UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; ESTRADIOL; GLUTAMATE DECARBOXYLASE 67; PARVALBUMIN; PLACEBO; PROGESTERONE; ESTROGEN;

ADJUVANT THERAPY; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CELL COUNT; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG IMPLANT; FEMALE; HIPPOCAMPUS; MAZE TEST; MENTAL DISEASE; MOUSE; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; OVARIECTOMY; PROTEIN EXPRESSION; SCHIZOPHRENIA; SILASTIC TUBE; SPATIAL MEMORY; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; DRUG EFFECTS; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; HETEROZYGOTE; HIPPOCAMPAL CA1 REGION; METABOLISM; PHYSIOLOGY;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN-DERIVED NEUROTROPHIC FACTOR; CA1 REGION, HIPPOCAMPAL; ESTRADIOL; ESTROGENS; FEMALE; GENE-ENVIRONMENT INTERACTION; HETEROZYGOTE; HIPPOCAMPUS; MAZE LEARNING; MICE; MICE, INBRED C57BL; OVARIECTOMY; PARVALBUMINS; SPATIAL MEMORY;

EID: 84927925216     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2014.143     Document Type: Article

References (99)

1. McClellan J, Stock S. Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 2013; 52: 976-990
2. Carlisle LL, McClellan J. Psychopharmacology of schizophrenia in children and adolescents. Pediatr Clin North Am 2011; 58: 205-218
3. Castle D, Sham P, Murray R. Differences in distribution of ages of onset in males and females with schizophrenia. Schizophr Res 1998; 33: 179-183
4. Häfner H, Behrens S, De Vry J, Gattaz WF. Oestradiol enhances the vulnerability threshold for schizophrenia in women by an early effect on dopaminergic neurotransmission. Evidence from an epidemiological study and from animal experiments. Eur Arch Psychiatry Clin Neurosci 1991; 241: 65-68
5. Riecher-Rössler A, Loffler W, Munk-Jorgensen P. What do we really know about late-onset schizophrenia? Eur Arch Psychiatry Clin Neurosci 1997; 247: 195-208
6. Krysta K, Murawiec S, Klasik A, Wiglusz MS, Krupka-Matuszczyk I. Sex-specific differences in cognitive functioning among schizophrenic patients. Psychiatr Danub 2013; 25: S244-S246
7. Cohen RZ, Seeman MV, Gotowiec A, Kopala L. Earlier puberty as a predictor of later onset of schizophrenia in women. Am J Psychiatry 1999; 156: 1059-1064
8. Nitsch R, Soriano E, Frotscher M. The parvalbumin-containing nonpyramidal neurons in the rat hippocampus. Anat Embryol (Berl) 1990; 181: 413-425
9. Chang SS, Renshaw DC. Psychosis and pregnancy. Compr Ther 1986; 12: 36-41
10. Häfner H. Gender differences in schizophrenia. Psychoneuroendocrinology 2003; 28: 17-54
11. Mahe V, Montagnon F, Nartowski J, Dumane A. Post-abortion mania. Br J Psychiatry 1999; 175: 389-390
12. Cotton SM, Lambert M, Schimmelmann BG, Foley DL, Morley KI, McGorry PD et al. Gender differences in premorbid, entry, treatment, and outcome characteristics in a treated epidemiological sample of 661 patients with first episode psychosis. Schizophr Res 2009; 114: 17-24
13. Morgan VA, Castle DJ, Jablensky AV. Do women express and experience psychosis differently from men? Epidemiological evidence from the Australian National Study of Low Prevalence (Psychotic) Disorders. Aust N Z J Psychiatry 2008; 42: 74-82
14. Seeman MV. Interaction of sex, age, and neuroleptic dose. Compr Psychiatry 1983; 24: 125-128
15. Brinton RD. Estrogen-induced plasticity from cells to circuits: predictions for cognitive function. Trends Pharmacol Sci 2009; 30: 212-222
16. Spencer JL, Waters EM, Romeo RD, Wood GE, Milner TA, McEwen BS. Uncovering the mechanisms of estrogen effects on hippocampal function. Front Neuroendocrinol 2008; 29: 219-237
17. Hampson E. Estrogen-related variations in human spatial and articulatorymotor skills. Psychoneuroendocrinology 1990; 15: 97-111
18. Hoff AL, Kremen WS, Wieneke MH, Lauriello J, Blankfeld HM, Faustman WO et al. Association of estrogen levels with neuropsychological performance in women with schizophrenia. Am J Psychiatry 2001; 158: 1134-1139
19. Ko YH, Joe SH, Cho W, Park JH, Lee JJ, Jung IK et al. Estrogen, cognitive function and negative symptoms in female schizophrenia. Neuropsychobiology 2006; 53: 169-175
20. Riecher-Rossler A, Hafner H, Stumbaum M, Maurer K, Schmidt R. Can estradiol modulate schizophrenic symptomatology? Schizophr Bull 1994; 20: 203-214
21. Huber TJ, Rollnik J, Wilhelms J, von zur Muhlen A, Emrich HM, Schneider U. Estradiol levels in psychotic disorders. Psychoneuroendocrinology 2001; 26: 27-35
22. Kulkarni J, de Castella A, Smith D, Taffe J, Keks N, Copolov D. A clinical trial of the effects of estrogen in acutely psychotic women. Schizophr Res 1996; 20: 247-252
23. Oades RD, Schepker R. Serum gonadal steroid hormones in young schizophrenic patients. Psychoneuroendocrinology 1994; 19: 373-385
24. Ghafari E, Fararouie M, Shirazi HG, Farhangfar A, Ghaderi F, Mohammadi A. Combination of estrogen and antipsychotics in the treatment of women with chronic schizophrenia: A double-blind, randomized, placebo-controlled clinical trial. Clin Schizophr Relat Psychoses 2013; 6: 172-176
25. Kulkarni J, de Castella A, Fitzgerald PB, Gurvich CT, Bailey M, Bartholomeusz C et al. Estrogen in severe mental illness: A potential new treatment approach. Arch Gen Psychiatry 2008; 65: 955-960
26. Kulkarni J, Gavrilidis E, Wang W, Worsley R, Fitzgerald PB, Gurvich C et al. Estradiol for treatment-resistant schizophrenia: A large-scale randomized-controlled trial in women of child-bearing age. Mol Psychiatry 2014
27. Huerta-Ramos E, Iniesta R, Ochoa S, Cobo J, Miquel E, Roca M et al. Effects of raloxifene on cognition in postmenopausal women with schizophrenia: A doubleblind, randomized, placebo-controlled trial. Eur Neuropsychopharmacol 2014; 24: 223-231
28. Raveendranathan D, Shivakumar V, Jayaram N, Rao NP, Venkatasubramanian G. Beneficial effects of add-on raloxifene in schizophrenia. Arch Womens Ment Health 2012; 15: 147-148
29. Shivakumar V, Venkatasubramanian G. Successful use of adjuvant raloxifene treatment in clozapine-resistant schizophrenia. Indian J Psychiatry 2012; 54: 394
30. Aguirre CC, Baudry M. Progesterone reverses 17beta-estradiol-mediated neuroprotection and BDNF induction in cultured hippocampal slices. Eur J Neurosci 2009; 29: 447-454
31. Hill RA. Interaction of sex steroid hormones and brain-derived neurotrophic factor-tyrosine kinase B signalling: relevance to schizophrenia and depression. J Neuroendocrinol 2012; 24: 1553-1561
32. Wu YC, Hill RA, Gogos A, van den Buuse M. Sex differences and the role of estrogen in animal models of schizophrenia: interaction with BDNF. Neuroscience 2013; 239: 67-83
33. Singh M, Meyer EM, Simpkins JW. The effect of ovariectomy and estradiol replacement on brain-derived neurotrophic factor messenger ribonucleic acid expression in cortical and hippocampal brain regions of female Sprague-Dawley rats. Endocrinology 1995; 136: 2320-2324
34. Miranda RC, Sohrabji F, Toran-Allerand CD. Presumptive estrogen target neurons express mRNAs for both the neurotrophins and neurotrophin receptors: A basis for potential developmental interactions of estrogen with the neurotrophins. Mol Cell Neurosci 1993; 4: 510-525
35. Sohrabji F, Miranda RC, Toran-Allerand CD. Identification of a putative estrogen response element in the gene encoding brain-derived neurotrophic factor. Proc Natl Acad Sci USA 1995; 92: 11110-11114
36. Scharfman HE, Maclusky NJ. Similarities between actions of estrogen and BDNF in the hippocampus: coincidence or clue? Trends Neurosci 2005; 28: 79-85
37. Blurton-Jones M, Tuszynski MH. Estradiol-induced modulation of estrogen receptor-beta and GABA within the adult neocortex: A potential transsynaptic mechanism for estrogen modulation of BDNF. J Comp Neurol 2006; 499: 603-612
38. Solum DT, Handa RJ. Estrogen regulates the development of brain-derived neurotrophic factor mRNA and protein in the rat hippocampus. J Neurosci 2002; 22: 2650-2659
39. Berchtold NC, Kesslak JP, Pike CJ, Adlard PA, Cotman CW. Estrogen and exercise interact to regulate brain-derived neurotrophic factor mRNA and protein expression in the hippocampus. Eur J Neurosci 2001; 14: 1992-2002
40. Dissen GA, Garcia-Rudaz C, Ojeda SR. Role of neurotrophic factors in early ovarian development. Semin Reprod Med 2009; 27: 24-31
41. Durany N, Michel T, Zochling R, Boissl KW, Cruz-Sanchez FF, Riederer P et al. Brainderived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res 2001; 52: 79-86
42. Thompson Ray M, Weickert CS, Wyatt E, Webster MJ. Decreased BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders. J Psychiatry Neurosci 2011; 36: 195-203
43. Chen ZY, Patel PD, Sant G, Meng CX, Teng KK, Hempstead BL et al. Variant brainderived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J Neurosci 2004; 24: 4401-4411
44. Zai GC, Zai CC, Chowdhury NI, Tiwari AK, Souza RP, Lieberman JA et al. The role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychotic-induced weight gain. Prog Neuropsychopharmacol Biol Psychiatry 2012; 39: 96-101
45. Zhang JP, Lencz T, Geisler S, DeRosse P, Bromet EJ, Malhotra AK. Genetic variation in BDNF is associated with antipsychotic treatment resistance in patients with schizophrenia. Schizophr Res 2013; 146: 285-288
46. Rybakowski JK. BDNF gene: functional Val66Met polymorphism in mood disorders and schizophrenia. Pharmacogenomics 2008; 9: 1589-1593
47. Niitsu T, Shirayama Y, Matsuzawa D, Hasegawa T, Kanahara N, Hashimoto T et al. Associations of serum brain-derived neurotrophic factor with cognitive impairments and negative symptoms in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 1836-1840
48. Glorioso C, Sabatini M, Unger T, Hashimoto T, Monteggia LM, Lewis DA et al. Specificity and timing of neocortical transcriptome changes in response to BDNF gene ablation during embryogenesis or adulthood. Mol Psychiatry 2006; 11: 633-648
49. Grosse G, Djalali S, Deng DR, Holtje M, Hinz B, Schwartzkopff K et al. Area-specific effects of brain-derived neurotrophic factor (BDNF) genetic ablation on various neuronal subtypes of the mouse brain. Brain Res Dev Brain Res 2005; 156: 111-126
50. Marin O. Interneuron dysfunction in psychiatric disorders. Nat Rev Neurosci 2012; 13: 107-120
51. Volman V, Behrens MM, Sejnowski TJ. Downregulation of parvalbumin at cortical GABA synapses reduces network gamma oscillatory activity. J Neurosci 2011; 31: 18137-18148
52. Benes FM, Kwok EW, Vincent SL, Todtenkopf MS. A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives. Biol Psychiatry 1998; 44: 88-97
53. Konradi C, Yang CK, Zimmerman EI, Lohmann KM, Gresch P, Pantazopoulos H et al. Hippocampal interneurons are abnormal in schizophrenia. Schizophr Res 2011; 131: 165-173
54. Zhang ZJ, Reynolds GP. A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia. Schizophr Res 2002; 55: 1-10
55. Lin LC, Sibille E. Reduced brain somatostatin in mood disorders: A common pathophysiological substrate and drug target? Front Pharmacol 2013; 4: 110
56. Wu YC, Du X, van den Buuse M, Hill RA. Sex differences in the adolescent developmental trajectory of parvalbumin interneurons in the hippocampus: A role for estradiol. Psychoneuroendocrinology 2014; 45: 167-178
57. Fanselow MS, Dong HW. Are the dorsal and ventral hippocampus functionally distinct structures? Neuron 2010; 65: 7-19
58. Caruso D, Pesaresi M, Abbiati F, Calabrese D, Giatti S, Garcia-Segura LM et al. Comparison of plasma and cerebrospinal fluid levels of neuroactive steroids with their brain, spinal cord and peripheral nerve levels in male and female rats. Psychoneuroendocrinology 2013; 38: 2278-2290
59. Klug M, Hill RA, Choy KH, Kyrios M, Hannan AJ, van den Buuse M. Long-term behavioral and NMDA receptor effects of young-adult corticosterone treatment in BDNF heterozygous mice. Neurobiol Dis 2012; 46: 722-731
60. Klug M, van den Buuse M. An investigation into "two hit" effects of BDNF deficiency and young-adult cannabinoid receptor stimulation on prepulse inhibition regulation and memory in mice. Front Behav Neurosci 2013; 7: 149
61. Usall J, Huerta-Ramos E, Iniesta R, Cobo J, Araya S, Roca M et al. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: A doubleblind, randomized, placebo-controlled trial. J Clin Psychiatry 2011; 72: 1552-1557
62. Cenquizca LA, Swanson LW. Spatial organization of direct hippocampal field CA1 axonal projections to the rest of the cerebral cortex. Brain Res Rev 2007; 56: 1-26
63. Han CJ, O'Tuathaigh CM, van Trigt L, Quinn JJ, Fanselow MS, Mongeau R et al. Trace but not delay fear conditioning requires attention and the anterior cingulate cortex. Proc Natl Acad Sci USA 2003; 100: 13087-13092
64. Jones MW, Wilson MA. Theta rhythms coordinate hippocampal-prefrontal interactions in a spatial memory task. PLoS Biol 2005; 3: e402
65. Lavenex PB, Amaral DG, Lavenex P. Hippocampal lesion prevents spatial relational learning in adult macaque monkeys. J Neurosci 2006; 26: 4546-4558
66. Sultan KT, Brown KN, Shi SH. Production and organization of neocortical interneurons. Front Cell Neurosci 2013; 7: 221
67. Murray AJ, Sauer JF, Riedel G, McClure C, Ansel L, Cheyne L et al. Parvalbuminpositive CA1 interneurons are required for spatial working but not for reference memory. Nat Neurosci 2011; 14: 297-299
68. Morris RG, Garrud P, Rawlins JN, O'Keefe J. Place navigation impaired in rats with hippocampal lesions. Nature 1982; 297: 681-683
69. Nyberg L, McIntosh AR, Cabeza R, Habib R, Houle S, Tulving E. General and specific brain regions involved in encoding and retrieval of events: what, where, and when. Proc Natl Acad Sci USA 1996; 93: 11280-11285
70. Squire LR. Memory and the hippocampus: A synthesis from findings with rats, monkeys, and humans. Psychol Rev 1992; 99: 195-231
71. Miller JF, Neufang M, Solway A, Brandt A, Trippel M, Mader I et al. Neural activity in human hippocampal formation reveals the spatial context of retrieved memories. Science 2013; 342: 1111-1114
72. Morgan MA, Pfaff DW. Effects of estrogen on activity and fear-related behaviors in mice. Horm Behav 2001; 40: 472-482
73. Gibbs RB. Levels of trkA and BDNF mRNA, but not NGF mRNA, fluctuate across the estrous cycle and increase in response to acute hormone replacement. Brain Res 1998; 810: 294
74. Scharfman HE, Mercurio TC, Goodman JH, Wilson MA, MacLusky NJ. Hippocampal excitability increases during the estrous cycle in the rat: A potential role for brainderived neurotrophic factor. J Neurosci 2003; 23: 11641-11652
75. Scharfman HE, MacLusky NJ. Estrogen and brain-derived neurotrophic factor (BDNF) in hippocampus: complexity of steroid hormone-growth factor interactions in the adult CNS. Front Neuroendocrinol 2006; 27: 415-435
76. Nakamura NH, McEwen BS. Changes in interneuronal phenotypes regulated by estradiol in the adult rat hippocampus: A potential role for neuropeptide Y. Neuroscience 2005; 136: 357-369
77. Blurton-Jones M, Tuszynski MH. Estrogen receptor-beta colocalizes extensively with parvalbumin-labeled inhibitory neurons in the cortex, amygdala, basal forebrain, and hippocampal formation of intact and ovariectomized adult rats. J Comp Neurol 2002; 452: 276-287
78. Deller T, Leranth C. Synaptic connections of neuropeptide Y (NPY) immunoreactive neurons in the hilar area of the rat hippocampus. J Comp Neurol 1990; 300: 433-447
79. Mody I, Pearce RA. Diversity of inhibitory neurotransmission through GABA(A) receptors. Trends Neurosci 2004; 27: 569-575
80. Whittington MA, Traub RD. Interneuron diversity series: inhibitory interneurons and network oscillations in vitro. Trends Neurosci 2003; 26: 676-682
81. Pouille F, Scanziani M. Routing of spike series by dynamic circuits in the hippocampus. Nature 2004; 429: 717-723
82. Fagiolini M, Fritschy JM, Low K, Mohler H, Rudolph U, Hensch TK. Specific GABAA circuits for visual cortical plasticity. Science 2004; 303: 1681-1683
83. Ernfors P, Lee KF, Jaenisch R. Mice lacking brain-derived neurotrophic factor develop with sensory deficits. Nature 1994; 368: 147-150
84. Lyons WE, Mamounas LA, Ricaurte GA, Coppola V, Reid SW, Bora SH et al. Brainderived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. Proc Natl Acad Sci USA 1999; 96: 15239-15244
85. Weickert CS, Ligons DL, Romanczyk T, Ungaro G, Hyde TM, Herman MM et al. Reductions in neurotrophin receptor mRNAs in the prefrontal cortex of patients with schizophrenia. Mol Psychiatry 2005; 10: 637-650
86. Hill RA, van den Buuse M. Sex-dependent and region-specific changes in TrkB signaling in BDNF heterozygous mice. Brain Res 2011
87. Lambert TJ, Castle DJ. Pharmacological approaches to the management of schizophrenia. Med J Aust 2003; 178: Suppl:S57-Suppl:S61
88. Lindenmayer JP, Khan A, Iskander A, Abad MT, Parker B. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. J Clin Psychiatry 2007; 68: 368-379
89. Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005; 8: 457-472
90. Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: A randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 2004; 161: 985-995
91. Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry 2007; 164: 428-436
92. Komulainen P, Pedersen M, Hanninen T, Bruunsgaard H, Lakka TA, Kivipelto M et al. BDNF is a novel marker of cognitive function in ageing women: The DR's EXTRA Study. Neurobiol Learn Mem 2008; 90: 596-603
93. Carreton O, Giralt A, Torres-Peraza JF, Brito V, Lucas JJ, Gines S et al. Agedependent decline of motor neocortex but not hippocampal performance in heterozygous BDNF mice correlates with a decrease of cortical PSD-95 but an increase of hippocampal TrkB levels. Exp Neurol 2012; 237: 335-345
94. Linnarsson S, Bjorklund A, Ernfors P. Learning deficit in BDNF mutant mice. Eur J Neurosci 1997; 9: 2581-2587
95. Liu IY, Lyons WE, Mamounas LA, Thompson RF. Brain-derived neurotrophic factor plays a critical role in contextual fear conditioning. J Neurosci 2004; 24: 7958-7963
96. Manning EE, van den Buuse M. BDNF deficiency and young-adult methamphetamine induce sex-specific effects on prepulse inhibition regulation. Front Cell Neurosci 2013; 7: 92
97. Begliuomini S, Casarosa E, Pluchino N, Lenzi E, Centofanti M, Freschi L et al. Influence of endogenous and exogenous sex hormones on plasma brain-derived neurotrophic factor. Hum Reprod 2007; 22: 995-1002
98. Podfigurna-Stopa A, Casarosa E, Luisi M, Czyzyk A, Meczekalski B, Genazzani AR. Decreased plasma concentrations of brain-derived neurotrophic factor (BDNF) in patients with functional hypothalamic amenorrhea. Gynecol Endocrinol 2013; 29: 817-820
99. Trotman HD, Holtzman CW, Ryan AT, Shapiro DI, MacDonald AN, Goulding SM et al. The development of psychotic disorders in adolescence: A potential role for hormones. Horm Behav 2013; 64: 411-419.